Cap Table. Each Existing Investor hereby confirms and acknowledges (i) that the Company equity set forth on the Cap Table attached hereto next to its name is a true, correct and accurate reflection of all of the Company equity owned by it and to which it is entitled, as of the date hereof, and immediately prior to and simultaneously with the Closing, and (ii) that except as set forth on the Cap Table attached hereto, it (A) does not, and shall not as of Closing, own any other Company securities, and (B) (except for preemptive rights and anti-dilution rights under certain circumstances, if any, in relation to future issuances by the Company, as set forth in the Amended AOA (as may be amended from time to time in accordance therewith and applicable law)) does not and shall not have any other rights to acquire any other Company securities from the Company, and (C) shall have no claims against the Company in connection with the issuance or non-issuance of any securities in the Company, and any such claims are hereby irrevocably waived in full by such Existing Investor.
Cap Table. As a duly authorized official of , I hereby attest that the information provided is a true and accurate representation of the information requested. Name: Title: Address: EXHIBIT B – Budget Aratana has budgeted $14.73 million for the R&D efforts associated with developing AT-001 and AT-002 to regulatory approval over 5 years. Of that total, approximately $6.56 million is budgeted for AT-001, while the remaining $8.17 million is estimated to be spent to develop AT-002 across the three possible indications. Over the next two years, Aratana has identified $4.0 million of this development program that can be conducted in Kansas with the collaborators identified below and in Section 1. 2012 Product Development Budget Kansas Collaborators Collaborator Product Amount Argenta AT-001 $ 469,457 AT-002 $ 770,660 Total $ 1,240,117 AlcheraBio AT-001 $ 375,000 AT-002 $ 360,000 Total $ 735,000 XenoMetrics AT-001 $ 50,000 AT-002 $ 150,000 Total $ 200,000 KCAS AT-002 $ 99,000 Total $ 99,000 Total Project Expenses $ 2,274,117 For work conducted beyond 2012, Aratana has indicated that approximately $2,000,000 of the Pivotal Safety and Efficacy trial work will be conducted in 2012 in Kansas with Kansas collaborators. As part of the proposed milestones, KBA staff has included the submission of an updated work plan and budget for these studies as part of Milestone # 4 of this proposed voucher. Aratana has entered into Master Service Agreements with AlcheraBio, Xenometrics and Argenta. Specific scope of work documents for the Argenta projects can be found in Appendix C and Appendix D of this document. Projects to be conducted by KCAS will be documented on individual work orders which will be provided to KBA as part of the Award Payment process. EXHIBIT C – Repayment Statute 74-99b18 Chapter 74.—STATE BOARDS, COMMISSIONS AND AUTHORITIES
Cap Table. A capitalization table of the Company, as of immediately prior and after consummation of the Initial Closing (as defined below), is attached hereto as Schedule 3.3(a).
Cap Table. The capitalization table in Annex 1 to this Schedule 3 is a true and correct representation of the Fully Diluted Share Capital as at the Signing Date displaying all the outstanding Shares and all the rights to Shares. All outstanding Shares have been legally and validly issued and fully paid for. To the Warrantor’s knowledge, none of the Shares are subject to any Encumbrances, except for any Encumbrances arising from the articles of association of the Company. There are no outstanding options, warrants, convertible loans, or any other rights to acquire any Shares other than those set out in the capitalization table in Annex 1 to this Schedule 3. In this Agreement, an “
Cap Table. The capitalization table in A nnex 1 to this S chedule 3 is a true and correct representation of the Fully Diluted Share Capital as at the Signing Date displaying all the outstanding Shares and all the rights to Shares. All outstanding Shares have been legally and validly issued and fully paid for. To the Warrantor’s knowledge, none of the Shares are subject to any Encumbrances, except for any Encumbrances arising from the articles of association of the Company. There are no outstanding options, warrants, convertible loans, or any other rights to acquire any Shares other than those set out in the capitalization table in A nnex 1 to this S chedule 3. In this Agreement, an “
